- October 31, 2018 08:25 (CET)
Cyxone (publ) announced today that the internationally renowned research house First Berlin Equity Research has published an independent analysis report of the company.
- October 23, 2018 08:25 (CEST)Regulatory
Cyxone AB (publ) announced today that the company has selected the clinical site that will carry out the drug candidate T20K's first in man study. The clinical site located in Western Europe has been carefully evaluated based on a number of crucial criteria and will treat the first healthy volunteers in the T20K clinical phase 1 study developed for the treatment of multiple sclerosis (MS). This means that the company is well aligned with the planned preparations for T20K's first clinical study prior to the start of recruitment of healthy volunteers as well as completion of the remaining preclinical program.
- August 17, 2018 14:23 (CEST)Regulatory
Cyxone AB (publ) announced today that the company changes Certified Adviser.
- August 17, 2018 08:00 (CEST)Regulatory
Summary of interim report
- August 15, 2018 10:00 (CEST)Regulatory
Cyxone AB (publ) announced today that the company has decided to bring forward the publication of the interim report for the period January-June 2018.
- July 10, 2018 10:31 (CEST)Regulatory
Cyxone AB (publ) announced today that the company’s second and last phase of the pilot study in inflammatory bowel disease (IBD) with its cyclotide technology has been concluded. The results add to the growing body of evidence around the cyclotide technology, deepening the understanding of this natural plant protein.
- June 29, 2018 14:25 (CEST)
Cyxone AB (publ) announced today that the company has appointed Mangold Fondkommission to provide market making services for the company’s share. The purpose of the market maker is to improve the liquidity of the share and reduce the difference between the buying and selling price. The assignment commences on July 2, 2018.
- June 1, 2018 15:31 (CEST)Regulatory
Cyxone AB (publ) announced today that the company has decided to complete the acquisition of drug candidate Rabeximod and issue approximately 1.9 million shares to complete the payment to OxyPharma AB. Cyxone entered into an acquisition agreement with OxyPharma in June 2017 for the drug candidate Rabeximod and now chooses to complete the transaction. The deal has strengthened Cyxone's development portfolio with a candidate in clinical phase II program and broadened the company's portfolio in autoimmune diseases.
- May 16, 2018 13:57 (CEST)Regulatory
Summary of the Interim Report
- April 23, 2018 14:14 (CEST)Regulatory
Cyxone announced today that the European Patent Office (EPO), has issued its formal intention to approve the company’s patent application regarding the company’s use of cyclotides as immunosuppressive drugs. The approval will strengthen the company’s patent portfolio and ensures the protection of the candidate T20K, which demonstrates beneficial pharmacological effect in preclinical studies against autoimmune diseases, such as multiple sclerosis (MS).